APOL1 (Apolipoprotein L1)

Class

Small-molecule APOL1 ion-channel inhibitor

Pathway

APOL1-mediated podocyte injury (APOL1-associated kidney disease)

Apolipoprotein L1 (APOL1) is a protein normally secreted into the bloodstream, where it helps the innate immune system kill certain trypanosome parasites. Two variants of the APOL1 gene, found almost exclusively in people of recent African ancestry, arose historically because they confer resistance to that infection. These same variants, however, predispose carriers to chronic kidney disease, including forms of focal segmental glomerulosclerosis and other non-diabetic kidney disorders grouped under APOL1-associated kidney disease. The disease-causing variants alter APOL1 so that, inside kidney cells called podocytes (specialized cells that maintain the filtration barrier in the kidney's glomeruli), the protein behaves as an overactive ion channel, letting ions cross cell membranes abnormally and injuring the cell. Over time this contributes to podocyte loss, protein leakage into urine, and progressive decline in kidney function. Small-molecule inhibitors of APOL1 aim to block this abnormal channel activity directly within podocytes, seeking to halt or slow kidney injury at its cellular origin rather than only managing downstream consequences such as high blood pressure or proteinuria. This mechanism matters broadly for genetically defined kidney disease affecting populations carrying these risk variants, an area with historically few disease-specific treatment options.